Nektar Therapeutics (NKTR) — Cash Flow Quality Index

Latest as of December 2024: -6.36x

Nektar Therapeutics (NKTR) has a Cash Flow Quality Index of -6.36x as of December 2024. Operating cash flow of $-46.19 Million is below net income of $7.26 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Nektar Therapeutics (NKTR) long-term investment share to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

-6.36x
Operating CF / Net Income

Operating Cash Flow

$-46.19 Million
USD

Net Income

$7.26 Million
USD

Data as of

Dec 2024
Most recent filing

Nektar Therapeutics Cash Flow Quality Index (2018–2018)

Historical Cash Flow Quality Index for Nektar Therapeutics across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how tangible is Nektar Therapeutics's equity to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Nektar Therapeutics (2018–2018)

Year-by-year earnings quality comparison for Nektar Therapeutics. For live market cap and the full company financial profile, see NKTR market cap overview.

Year Quality Index Operating CF (USD) Net Income YoY Change
2018 1.05x $718.21 Million $681.31 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.